Skip to main content

Fiscal Wizard · Single-issue tearsheet

XERS / Jun 21, 2026 Run #7323

XERS

Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Composite verdict

F 24.7 / 100
Bearish setup · Mean Reversion 10 drivers · 7 gates blocking
  • Williams %R
  • Multi Top/Bottom
  • Stochastic Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 39th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Neutral 48Mean-reversion Bearish 6

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -88%
Asset value $0.08Earnings power value $0.97Price $6.95

Priced above its no-growth earnings power value ($0.97/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

48.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
OCF to Net Income 0
Asset Turnover 79
Cash Conversion 0

Technicals Bearish

0.4 / 100

Bearish setup leads (Williams %R, Multi Top/Bottom, Stochastic Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Williams %R 8
Multi Top/Bottom 14
Commodity Channel Index 17

Risk Gates

7 blocking 4 caution

7 guards active, 22 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for XERS.